Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VH4004280 and VH4011499 capsid inhibitors in HIV-1 treatment-naïve adults
NCT06039579Phase 2Completed
- Sponsor
- ViiV Healthcare
- Start
- Oct 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of VH-4004280 and VH4011499 in human immunodeficiency virus type 1 infection (HIV-1) (8 arms), sponsored by ViiV Healthcare. Primary endpoints: Maximum Change From Baseline in Plasma HIV-1 RNA log10 - VH4004280 and Maximum Change From Baseline in Plasma HIV-1 RNA log10 - VH4011499. Started Oct 2023; status: completed.
02
Drugs
VH-4004280VH4011499
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT06039579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06039579.